-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Rubius Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2017 to Q4 2022.
- Rubius Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2022 was -$20.1M, a 63.4% increase year-over-year.
- Rubius Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2022 was -$180M, a 8.59% increase year-over-year.
- Rubius Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$180M, a 8.59% increase from 2021.
- Rubius Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$197M, a 17.2% decline from 2020.
- Rubius Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$168M, a 2.61% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)